Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2018-08-28 |
SGS (Switzerland) |
|
|
construction of new premises |
Technology - Services |
Construction of new premises |
2018-08-28 |
Allogene Therapeutics (USA - CA) |
senior vice president |
|
nomination |
Cancer - Oncology |
Nomination |
2018-08-23 |
Bluebird bio (USA - MA) Gritstone Oncology (USA - CA) |
tumor-specific targets and natural T-cell receptors (TCRs) |
|
research - development - commercialisation |
Cancer - Oncology |
Research agreement |
2018-08-16 |
BioNTech (Germany) Pfizer (USA - NY) |
mRNA-based flu vaccines |
influenza (flu) |
research - development - R&D |
Infectious diseases |
Development agreement |
2018-08-14 |
Actavalon (USA - CA) |
member of the board of directors |
|
nomination |
Cancer - Oncology |
Nomination |
2018-08-14 |
Allogene Therapeutics (USA - CA) |
chief development officer |
|
nomination |
Cancer - Oncology |
Nomination |
2018-08-08 |
Sarepta Therapeutics (USA - MA) Lacerta Therapeutics (USA - Fl) |
AAV-based CNS-targeted gene therapies |
CNS diseases |
licensing |
CNS diseases |
Licensing agreement |
2018-08-07 |
Infinity Pharmaceuticals (USA - MA) |
|
|
nomination |
Cancer - Oncology |
Nomination |
2018-08-07 |
apceth (Germany) |
|
|
validation of a production plant |
Technology - Services |
Production agreement |
2018-08-06 |
Allergan (Ireland) Editas Medicine (USA - MA) |
up to five of Editas Medicine's genome-editing ocular programs, including EDIT-101 for the treatment of LCA10 |
Leber congenital amaurosis type 10 (LCA10) |
development - licensing |
Rare diseases - Genetic diseases - Ophtalmological diseases |
Exercise of an option agreement |
2018-08-06 |
Boehringer Ingelheim (Germany) Oxford Biomedica (UK) UK Cystic Fibrosis Gene Therapy Consortium (UK) Imperial Innovations (UK) |
replication-deficient lentiviral vector in an inhaled formulation, to introduce a healthy copy of the CFTR gene into the cells of the lung |
cystic fibrosis |
collaboration |
Rare diseases - Genetic diseases - Respiratory diseases |
Collaboration agreement |
2018-08-06 |
Bluebird bio (USA - MA) Regeneron Pharmaceuticals (USA - NY) |
immune cell therapies |
|
research - development - R&D - commercialisation |
Cancer - Oncology |
Collaboration agreement |
2018-08-03 |
HTG Molecular Diagnostics (USA - AZ) Oncologie (USA - MA) |
biomarkers associated with Oncologie’s Immuno-oncology pipeline |
|
development |
|
Development agreement |
2018-08-02 |
Atlantic Healthcare (UK) |
US president and chief executive officer |
|
nomination |
Inflammatory diseases - Gastrointestinal diseases |
Nomination |
2018-08-02 |
Orchard Therapeutics (UK) |
member of the board of directors |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
2018-08-02 |
Akcea Therapeutics (USA - CA), a subsidiary of Ionis Pharmaceuticals (USA - CA) PTC Therapeutics (USA - NJ) |
Tegsedi™ (inotersen) and Waylivra™ (volanesorsen) |
hereditary transthyretin amyloidosis (hATTR), familial chylomicronemia syndrome (FCS) |
commercialisation |
Rare diseases - Genetic diseases |
Commercialisation agreement |
2018-08-01 |
BioNTech (Germany) SiO2 Medical Products (“SMP”) (USA - Ala) |
packaging and application devices for mRNA therapeutics |
|
collaboration |
Technology - Services |
Collaboration agreement |
2018-08-01 |
Celyad (Belgium) |
member of the board of directors |
|
nomination |
Cancer - Oncology |
Nomination |
2018-07-30 |
Retrotope (USA - CA) |
chief medical officer |
Rare diseases |
nomination |
|
Nomination |
2018-07-25 |
GSK (UK) 23andme (USA - CA) |
|
|
collaboration - research - development |
|
Collaboration agreement |